Generics Global Group of Eight (G8) Industry Guide 2019-2028
Summary
The G8 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The G8 countries contributed $1,61,715.9 million in 2023 to the global generics industry, with a compound annual growth rate (CAGR) of 5.8% between 2019 and 2023. The G8 countries are expected to reach a value of $2,15,698.2 million in 2028, with a CAGR of 5.9% over the 2023-28 period.
- Among the G8 nations, the US is the leading country in the generics industry, with market revenues of $74,229.0 million in 2023. This was followed by Germany and the UK, with a value of $27,662.3 and $15,516.9 million, respectively.
- The US is expected to lead the generics industry in the G8 nations with a value of $98,531.3 million in 2016, followed by Germany and the UK with expected values of $33,345.6 and $23,397.0 million, respectively.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the G8 generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 generics market
- Leading company profiles reveal details of key generics market players’ G8 operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the G8 generics market with five year forecasts by both value and volume
- Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country
Reasons To Buy
- What was the size of the G8 generics market by value in 2023?
- What will be the size of the G8 generics market in 2028?
- What factors are affecting the strength of competition in the G8 generics market?
- How has the market performed over the last five years?
- How large is the G8 generics market in relation to its regional counterparts?